Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
FDF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Banamine
2. Finadyne
3. Sch 14714 Meglumine
1. 42461-84-7
2. Flunixin Meglumin
3. Banamine
4. Sch 14714 Meglumine
5. Flumeglumine
6. Flunixin-s
7. Flunixin N-methylglucanine
8. Flunixin (meglumine)
9. Flunixin Meglumine Salt
10. Sch-14714 Meglumine
11. Nsc-759583
12. 8y3jk0jw3u
13. Finadyne
14. Chebi:76144
15. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
16. 1-deoxy-1-(methylamino)-d-glucitol 2-(2-methyl-3-(perfluoromethyl)anilino)nicotinate
17. 3-pyridinecarboxylic Acid, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-, Compd. With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
18. Banamine (veterinary)
19. Flunixin Meglumine [usan]
20. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;2-[2-methyl-3-(trifluoromethyl)anilino]pyridine-3-carboxylic Acid
21. Smr000875279
22. Sr-05000001901
23. Einecs 255-836-0
24. Unii-8y3jk0jw3u
25. Flunixin Meglumine [usan:usp]
26. Flunixin Meglumine (usp)
27. Banamine [vetarynary] (tn)
28. Schembl43691
29. Bspbio_002558
30. 2-(alpha(sup 3),alpha(sup 3),alpha(sup 3)-trifluoro-2,3-xylidino)nicotinic Acid Compound With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
31. Mls001333159
32. Mls002153985
33. Spectrum1505113
34. Chembl1733447
35. Hms2093i10
36. Hms2234k05
37. Hms3884j07
38. Pharmakon1600-01505113
39. Flunixin Meglumine [mart.]
40. Flunixin Meglumine [usp-rs]
41. Hy-b0386
42. Flunixin Meglumine Salt [mi]
43. Mfcd01725419
44. Nsc759583
45. S2108
46. Flunixin Meglumine, >=98% (hplc)
47. Akos015895954
48. Ac-6012
49. Ccg-213338
50. Flunixin Meglumine [green Book]
51. Ks-5126
52. Nsc 759583
53. Ncgc00180889-01
54. 2-((2-methyl-3-(trifluoromethyl)-phenyl)amino)-3-pyridinecarboxylic Acid With Meglumine Compounded
55. D-glucitol, 1-deoxy-1-(methylamino)-, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylate (salt)
56. Flunixin Meglumine [usp Monograph]
57. Sw196448-3
58. Flunixin Meglumine 100 Microg/ml In Methanol
59. D04216
60. H10204
61. Ab00920714_05
62. Ab00920714_06
63. 461f847
64. Flunixin Meglumine 100 Microg/ml In Acetonitrile
65. Q-201124
66. Sr-05000001901-1
67. Sr-05000001901-3
68. Q27145782
69. Flunixin Meglumine, European Pharmacopoeia (ep) Reference Standard
70. Flunixin Meglumine, United States Pharmacopeia (usp) Reference Standard
71. Flunixin Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material
72. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(2-methyl-3-(trifluoromethyl)phenylamino)nicotinate
73. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
74. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinate
75. 2-(.alpha.(sup 3),.alpha.(sup 3),.alpha.(sup 3)-trifluoro-2,3-xylidino)nicotinic Acid Compound With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
76. 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)
Molecular Weight | 491.5 g/mol |
---|---|
Molecular Formula | C21H28F3N3O7 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 9 |
Exact Mass | 491.18793473 g/mol |
Monoisotopic Mass | 491.18793473 g/mol |
Topological Polar Surface Area | 175 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 510 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antipyretics
Drugs that are used to reduce body temperature in fever. (See all compounds classified as Antipyretics.)
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10765
Submission : 1994-03-10
Status : Inactive
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Certificate Number : CEP 2022-160 - Rev 00
Issue Date : 2024-08-08
Type : Chemical
Substance Number : 1696
Status : Valid
Certificate Number : R1-CEP 2006-141 - Rev 00
Issue Date : 2012-03-13
Type : Chemical
Substance Number : 1696
Status : Valid
Certificate Number : CEP 2022-493 - Rev 00
Issue Date : 2024-05-13
Type : Chemical
Substance Number : 1696
Status : Valid
NDC Package Code : 13371-718
Start Marketing Date : 2010-07-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6547
Submission : 2023-07-26
Status : Active
Type : II
Certificate Number : R1-CEP 2016-133 - Rev 00
Issue Date : 2022-04-14
Type : Chemical
Substance Number : 1696
Status : Valid
NDC Package Code : 67321-001
Start Marketing Date : 2017-10-19
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6162
Submission : 2016-08-26
Status : Active
Type : II
Certificate Number : R1-CEP 2006-109 - Rev 00
Issue Date : 2014-09-11
Type : Chemical
Substance Number : 1696
Status : Valid
NDC Package Code : 21222-003
Start Marketing Date : 2012-08-06
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5354
Submission : 1991-05-02
Status : Active
Type : II
Certificate Number : CEP 2022-371 - Rev 03
Issue Date : 2024-04-04
Type : Chemical
Substance Number : 1696
Status : Valid
Certificate Number : R1-CEP 2016-099 - Rev 00
Issue Date : 2022-07-26
Type : Chemical
Substance Number : 1696
Status : Valid
NDC Package Code : 62635-004
Start Marketing Date : 2022-10-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 6501
Submission : 2022-12-30
Status : Active
Type : II
Certificate Number : CEP 2015-371 - Rev 01
Issue Date : 2024-11-19
Type : Chemical
Substance Number : 1696
Status : Valid
VMF Number : 6114
Submission : 2015-09-02
Status : Active
Type : II
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Flunixin Meglumine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Flunixin Meglumine, including repackagers and relabelers. The FDA regulates Flunixin Meglumine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Flunixin Meglumine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Flunixin Meglumine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Flunixin Meglumine supplier is an individual or a company that provides Flunixin Meglumine active pharmaceutical ingredient (API) or Flunixin Meglumine finished formulations upon request. The Flunixin Meglumine suppliers may include Flunixin Meglumine API manufacturers, exporters, distributors and traders.
click here to find a list of Flunixin Meglumine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Flunixin Meglumine DMF (Drug Master File) is a document detailing the whole manufacturing process of Flunixin Meglumine active pharmaceutical ingredient (API) in detail. Different forms of Flunixin Meglumine DMFs exist exist since differing nations have different regulations, such as Flunixin Meglumine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Flunixin Meglumine DMF submitted to regulatory agencies in the US is known as a USDMF. Flunixin Meglumine USDMF includes data on Flunixin Meglumine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Flunixin Meglumine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Flunixin Meglumine suppliers with USDMF on PharmaCompass.
A Flunixin Meglumine CEP of the European Pharmacopoeia monograph is often referred to as a Flunixin Meglumine Certificate of Suitability (COS). The purpose of a Flunixin Meglumine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Flunixin Meglumine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Flunixin Meglumine to their clients by showing that a Flunixin Meglumine CEP has been issued for it. The manufacturer submits a Flunixin Meglumine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Flunixin Meglumine CEP holder for the record. Additionally, the data presented in the Flunixin Meglumine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Flunixin Meglumine DMF.
A Flunixin Meglumine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Flunixin Meglumine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Flunixin Meglumine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Flunixin Meglumine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Flunixin Meglumine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Flunixin Meglumine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Flunixin Meglumine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Flunixin Meglumine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Flunixin Meglumine suppliers with NDC on PharmaCompass.
Flunixin Meglumine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Flunixin Meglumine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Flunixin Meglumine GMP manufacturer or Flunixin Meglumine GMP API supplier for your needs.
A Flunixin Meglumine CoA (Certificate of Analysis) is a formal document that attests to Flunixin Meglumine's compliance with Flunixin Meglumine specifications and serves as a tool for batch-level quality control.
Flunixin Meglumine CoA mostly includes findings from lab analyses of a specific batch. For each Flunixin Meglumine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Flunixin Meglumine may be tested according to a variety of international standards, such as European Pharmacopoeia (Flunixin Meglumine EP), Flunixin Meglumine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Flunixin Meglumine USP).
LOOKING FOR A SUPPLIER?